ProCE Banner Activity

FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia

Podcast Episodes

In this podcast, experts answer pressing questions on optimizing the use of pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with ALL.

Released: February 20, 2023

Expiration: February 19, 2024



Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Emily Curran

Emily Curran, MD

Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Kjeld Schmiegelow

Kjeld Schmiegelow, MD, DMSci

Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from

Jazz Pharmaceuticals Inc

Program Director Disclosure

Daniel J. DeAngelo, MD, PhD: researcher: AbbVie, Blueprint, GlycoMimetics, Novartis; consultant: AbbVie, Agios, Amgen, Autolus, Blueprint, Forty-Seven, Gilead Sciences, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, Takeda; DSMB: Daiichi-Sanko, Fibrogen.

Faculty Disclosure

Kjeld Schmiegelow, MD, DMSci: consultant/advisor/speaker: Jazz, Servier; researcher: Novo Nordisk Foundation.

Emily Curran, MD: consultant/advisor/speaker: Amgen, Incyte, Kite, Pfizer, Servier, Tempus.